Overview
The current study is a pilot for the GRF project entitled "Predicting illness trajectories in fully remitted major depression using concurrent TBS/fNIRS". The project aims to determine whether immediate prefrontal excitability modulated by intermittent theta-burst stimulation (iTBS) is altered in remitted major depressive disorder (rMDD) and therefore classifies as a potential trait marker to predict the incidence of recurrence. In the present cross-sectional study, we will recruit four clusters of population, including patients diagnosed with rMDD, currently depressed patients with varying numbers of episodes, healthy subjects, and never-depressed healthy subjects with elevated risk for MDD (defined as having a first-degree relative with a history of depression), to investigate the relationship between the number of prior episodes, cognitive function, and TBS-induced instantaneous brain activity change in the presumed neuropathological prefrontal cortex (PFC).
Eligibility
Inclusion Criteria:
- rMDD patients: (a) aged 18 to 65; (b) a clinical diagnosis of recurrent depressive disorder by an experienced psychiatrist but currently in full remission (ICD 11, 6A71.7) according to results of the Mini International Neuropsychiatric Interview (MINI) and the Patient Health Questionnaire (PHQ-9), with a score ≤ 4; (c) at least two previous MDEs within the last 10 years; (d) no or stable (≥4 weeks) psychopharmacological medication.
Current MDD patients: (a) aged 18 to 65; (b) a clinical diagnosis of current unipolar
depressive disorder by an experienced psychiatrist according to DSM-IV; (c) no or stable
(≥4 weeks) psychopharmacological medication.
HCs: (a) aged 18 to 65 and (b) healthiness based on history and psychiatric assessment.
never-depressed HCs with elevated risk for MDD (HR-HCs): (a) aged 18 to 65, (b) healthiness
based on history and psychiatric assessment and (c) with a family history of psychiatric
illnesses.
Exclusion Criteria:
- rMDD patients: (a) severe internal diseases; (b) neurological disorders or a history
of severe head injuries; (c) current psychiatric comorbidities, including addiction;
(d) pregnancy; (e) common fNIRS and TMS exclusion criteria, such as a history of brain
surgery, head injury, cardiac pacemaker, deep brain stimulation, intracranial metallic
particles, history of seizures, and antiepileptics and benzodiazepines corresponding
to a dose of >1 mg lorazepam/d.
MDD patients: (a) severe internal diseases; (b) neurological disorders or a history of
severe head injuries; (c) Axis-I disorders and history of alcohol or substance abuse or
past co-morbid axis-I disorders being the likely primary cause of the depressive syndrome
within the past 6 months; (d) pregnancy; (e) common fNIRS and TMS exclusion criteria, such
as a history of brain surgery, head injury, cardiac pacemaker, deep brain stimulation,
intracranial metallic particles, history of seizures, and antiepileptics and
benzodiazepines corresponding to a dose of >1 mg lorazepam/d.
HCs: (a) medical history of a major systemic illness or a neurological or psychiatric
disorder; (b) psychiatric disorders in their first-degree relatives; (c) pregnancy; and (d)
common fNIRS and TMS exclusion criteria as stated above.